FDA/NIH diabetes public meeting
Executive Summary
FDA and National Institutes of Health will hold a joint public meeting May 13 and 14 to discuss the treatment of type 1 and type 2 diabetes mellitus. The FDA/NIH collaboration is part of Commissioner McClellan's strategic plan to develop a regulatory framework that would encourage the development of treatments in high-need areas, such as diabetes, cancer, obesity and lupus (1"The Pink Sheet" Feb. 10, 2003, p. 5)...
You may also be interested in...
FDA Drug Development Guidances: Oncology, Diabetes, Obesity Are Priorities
FDA's top priorities for drug development guidances are in the areas of oncology, diabetes and obesity
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.